Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
RMD Open|February 27, 2020
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritisMasayoshi Harigai, Kevin Winthrop, Tsutomu Takeuchi, et al.
The Lancet. Rheumatology|January 26, 2024
Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysisMark C Genovese, Josef S Smolen, Tsutomu Takeuchi, et al.
The British Journal of Dermatology|February 10, 2023
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trialsBrett King, Arash Mostaghimi, Yutaka Shimomura, et al.
The New England Journal of Medicine|March 25, 2022
Two Phase 3 Trials of Baricitinib for Alopecia AreataBrett King, Manabu Ohyama, Ohsang Kwon, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 15, 2024
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 PopulationJonathan Corren, Stanley J Szefler, Ellen Sher, et al.
Experimental and Therapeutic Medicine|September 13, 2012
Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutationsWen-Shuo Wu, Yuh-Min Chen, Chun-Ming Tsai, et al.
Clinical Interventions in Aging|February 27, 2020
Teriparatide in East Asian Postmenopausal Women with Osteoporosis in a Real-World Setting: A Baseline Analysis of the Asia and Latin America Fracture Observational Study (ALAFOS)Chung-Hwan Chen, Seung-Jae Lim, Jong-Keon Oh, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE studyGee-Chen Chang, Chien-Hua Tseng, Kuo-Hsuan Hsu, et al.
Pageof 3